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Am J Med Genet Part A 173A:375–383.Efficacy and safety of elosulfase alfa enzyme replacement therapy
(ERT) were assessed in an open-label, phase 2, multi-national
study in Morquio A patients aged 5 years unable to walk 30
meters in the 6-min walk test. Patients received elosulfase alfa
2.0mg/kg/week intravenously for 48 weeks. Efficacy measures
were functional dexterity, pinch/grip strength, mobility in a
modified timed 25-foot walk, pain, quality of life, respiratory
function, and urine keratan sulfate (KS). Safety/tolerability was
also assessed. Fifteen patients received elosulfase alfa, three
patients discontinued ERT due to adverse events (two were
grade 3 drug-related adverse events, the other was not drug-
related), and two patientsmissed>20% of planned infusions; 10
completed treatment through 48 weeks and received 80% of
planned infusions (Modified Per Protocol [MPP] population).
The study population had more advanced disease than that
enrolled in other trials. From baseline to week 48, MPP data
showed biochemical efficacy (urine KS decreased 52.4%). The
remaining efficacy results were highly variable due to challenges
in test execution because of severe skeletal and joint abnormali-
ties, small sample sizes, and clinical heterogeneity among
patients. Eight patients showed improvements in one or more
outcomemeasures; several patients indicated improvements not
captured by the study assessments (e.g., increased energy, func-
tional ability). The nature of adverse events was similar to other
elosulfase alfa studies. This study illustrates the considerable
challenges in objectively measuring impact of ERT in very2016 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc. 375
376 AMERICAN JOURNAL OF MEDICAL GENETICS PART AdisabledMorquio A patients and highlights the need to examine
results on an individual basis.
 2016 The Authors. American Journal of Medical Genetics Part A Published by
Wiley Periodicals, Inc.
Key words: mucopolysaccharidosis IV; safety; physical endur-
ance; GALNS protein, human [supplementary concept]; enzyme
replacement therapy; mobility limitation
INTRODUCTION
Morquio A syndrome or mucopolysaccharidosis (MPS) IVA is an
autosomal recessive lysosomal storage disorder caused by deficien-
cies in the glycosaminoglycan (GAG)-degrading enzyme N-
acetylgalactosamine-6-sulfatase (GALNS). Lack of GALNS activity
results in progressive accumulation of keratan sulfate (KS) and
chondroitin-6-sulfate in lysosomes [Morris et al., 1994]. The
resulting cellular and organ dysfunction leads to an array of
progressively worsening clinical manifestations. Morquio A
patients typically show musculoskeletal and joint issues, including
short stature, short neck, chest, spine, hip, and knee abnormalities,
atlantoaxial instability, and wrist deformity and hypermobility
[Harmatz et al., 2013; Hendriksz et al., 2015a]. In addition, patients
frequently present with non-skeletal manifestations such as cardio-
respiratory compromise, spinal cord compression and myelopa-
thy, corneal clouding, hearing loss, hepatosplenomegaly, and
dental abnormalities [Harmatz et al., 2013; Hendriksz et al.,
2013, 2015a]. Musculoskeletal abnormalities, joint pain, cardiore-
spiratory compromise, and/or myelopathy frequently result in
limited endurance and mobility [Harmatz et al., 2013]. In a study
including 36 children and 27 adults with Morquio A, 44% of
children and 85% of adults were using a wheelchair, illustrating the
progressive nature of the disease that leads to decline in walking
ability [Hendriksz et al., 2014b].
The only approved disease-specific therapy for patients with
Morquio A syndrome is elosulfase alfa (VIMIZIM
1
, BioMarin
Pharmaceutical Inc., Novato, CA) enzyme replacement therapy
(ERT). The pivotal phase 3 study (MOR-004; clinicaltrials.gov
#NCT01275066) included 176 Morquio A patients able to walk
30 and325m in the 6-min walk test (6MWT). In these patients,
elosulfase alfa 2.0mg/kg/week treatment was associated with a
significant improvement in endurance in the 6MWT, a rapid
and sustained reduction in urine KS levels (40.7%), and clinically
meaningful and sustained improvements in respiratory function,
growth, and quality of life [Hendriksz et al., 2014a, 2015b].
The extension of this study (MOR-005; clinicaltrials.gov
#NCT01415427) showed sustained improvement in the 6MWT
over 120 weeks. Long-term 6MWT improvements were similar in
patients with baseline 6MWT distance200 and>200m and with
and without walking aids [Hendriksz et al., 2016b]. In addition, a
phase 2 study (MOR-008; clinicaltrials.gov # NCT01609062)
including 25 patients with Morquio A with relatively good endur-
ance (able to walk 200m at baseline in the 6MWT) suggested a
positive impact of ERT on exercise capacity, muscle strength, and
pain [Burton et al., 2015]. Here we present the results of MOR-006
(clinicaltrials.gov #NCT01697319), a phase 2 study designed toassess the efficacy and safety of elosulfase alfa in more severely
affected Morquio A patients, as defined by limited ambulation
(unable to walk 30m in the 6MWT).MATERIALS AND METHODS
Study Design and Patient Selection
MOR-006 was a phase 2, open-label, multi-national study. Criteria
for enrollment included confirmed diagnosis of Morquio A syn-
drome, age5 years, and inability to walk30m in the 6MWT at
the screening visit. Patients received weekly intravenous (IV)
infusions of 2.0mg/kg elosulfase alfa for 48 consecutive weeks
and were then given the option to participate in an extension phase
of the study for up to 96 weeks. All patients were pretreated with an
appropriate dose of (non-sedating) antihistamine medication
approximately 30min to 1 hr prior to infusion to avoid hypersensi-
tivity reactions associated with the administration of elosulfase alfa.
Antipyretic medications could also be given at the discretion of
the investigator. For patients with a history of reactions temporally
related todrug infusionor other risk factors (e.g., history of allergies,
infection, recent immunization), a sedating antihistamine could be
administered, and premedication with additional agents such as H2
blockers, montelukast sodium, or steroids could be considered.
The research was prospectively reviewed and approved by a duly
constituted ethics committee.Efficacy Evaluation
Primary efficacy measures. Supplementary file 1 provides a
schedule of the efficacy assessments performed during the study.
Efficacy results are not presented beyond the initial 48 week
treatment phase of the study as not all patients continued with
assessments in the extension phase. Primary efficacy measures,
assessed at baseline and then every 12 weeks, were upper extremity
function, mobility, pain, and self-care and functional abilities.
Upper extremity function was assessed using the functional
dexterity test (FDT) and grip/pinch tests. The FDT is a validated
and timed dexterity test that assesses the ability to use the hand in
daily tasks [Aaron and Jansen, 2003; Lee-Valkov et al., 2003].
Patients were allowed to stabilize the wrist by resting the forearm
on the table during the test.
A grip-strength dynamometer was used to measure grip
strength. One set of measurements was performed with the subject
resting the elbow and forearm on the table, and a second set was
obtained with the wrist unsupported, if feasible. According to the
protocol, patients had to be seated in appropriately sized chairs that
allowed their feet to be flat on the floor. The upper extremity to be
tested needed to be positioned so that the shoulder was abducted
and neutrally rotated, the elbow was flexed at 90˚, the forearm was
in a neutral position, and the wrist was 0–30˚ in extension. Three
measurements were obtained for each hand, with a 20-sec rest
between each trial.
A pinch meter was used to measure pinch strength. Each patient
was tested with the elbow at 90˚, the forearm neutral, and the wrist
in neutral deviation. One set of measurements (three trials) was
performed with the patient resting the elbow and forearm on the
HARMATZ ET AL. 377table, and a second set was obtained with the wrist unsupported, if
feasible.
Basic mobility was assessed in a modified version of the timed
25-foot walk (T25FW), which was originally developed for patients
with multiple sclerosis [Polman and Rudick, 2010]. Patients could
use assistive devices when doing this task. Unlike in the original
test, they could “walk” on their knees, crawl, or roll, if this was their
usual method of ambulation. The score for the T25FW was the
average of the two completed attempts.
Pain was assessed using the Brief Pain Inventory short form
(BPI-SF) in adult patients (18 years) and the Adolescent Pediatric
Pain Tool (APPT) in children (<18 years). The BPI-SF provides
information on pain intensity, as well as the degree to which pain
interferes with function [http://www.mdanderson.org/education-
and-research/departments-programs-and-labs/departments-and-
divisions/symptom-research/symptom-assessment-tools/
BPI_UserGuide.pdf]. The APPT is a validated, multi-dimensional
pain assessment tool for children and adolescents, which measures
the location, quality, and intensity of pain [Jacob et al., 2014].
Quality of life was assessed using the Pediatric Outcomes Data
Collection Instrument (PODCI) in children (<18 years) [Daltroy
et al., 1998] and the short form-36 (SF-36) version 2 health survey
in adults (18 years) (www.sf-36.org/tools/sf36.shtml). The
PODCI assesses the overall health, pain, and ability to participate
in normal daily activities, as well as in more vigorous activities
associated with young people and has previously shown measur-
able improvements during ERT in patients with MPS II [White
et al., 2010]. The scale scores were normalized such that a normal
individual will have a score of 50 and standard deviation (SD) of 10
and lower scores indicated higher levels of disability (normative
scale scoring: http://www.aaos.org/CustomTemplates/Content.
aspx?id = 22831&ssopc = 1#pedsref). The SF-36 is a validated
36-item questionnaire that assesses eight sub-items in two sub-
domains, that is, the Physical Component Summary (PCS) and the
Mental Component Summary (MCS) (www.sf-36.org/tools/sf36.
shtml) [Miller et al., 2010]. Each scale as well as the two summary
scores range from 0 to 100, with higher scores indicating better
quality of life and a score of 50 (SD 10) being representative of the
general population.
Secondary and tertiary efficacy measures. Supplementary file
1 shows the schedule of assessments of secondary and tertiary efficacy
measures. Secondary efficacy measures were respiratory function
and urine KS levels (normalized to creatinine). Tertiary efficacy
measures included the 6MWT, anthropometric measurements
(growth), and a patient impressionquestionnaire (PIQ). In addition,
radiographs of the lumbar spine, lower extremities, and hand/wrist
and DXA scans (bone density) of the lumbar spine were performed
for some patients at the discretion of the investigator and/or study
site. At each visit, patients were also asked about the number of times
they had taken analgesic medications for Morquio A disease in the
past week.Safety Evaluation
Safety was assessed throughout the initial 48-week study
period and during the extension phase by evaluating clinical
laboratory tests, physical examinations, immunogenicity testing,echocardiograms, electrocardiograms, and magnetic resonance
imaging scans of the cervical spine. Adverse events (AEs) and
changes in concomitant medication were also recorded through-
out the study. Vital signs were measured on infusion days. Serum
samples were collected for immunogenicity testing prior to dose
administration at baseline and at weeks 2, 4, 6, 12, 24, 36, 48, 72,
and 96.Statistical Methods
As several patients from the ITT population were not compliant
with the protocol or did not remain in the study for 48 weeks due
to logistical issues, acute disease related to Morquio A, or adverse
reactions to the study drug, descriptive statistics of efficacy
measured from baseline through week 48 are presented for a
Modified Per Protocol (MPP) population. The protocol origi-
nally excluded patients who missed six or more infusions from
baseline through 48 weeks. Given the small sample size, criteria
were adjusted to 20% missed infusions, establishing the MPP
population.
For the purpose of creating individual patient spider plots,
variables (FDT, T25FW, quality of life [PODCI or SF-36 PCS],
pain [APPT or BPI-SF], forced vital capacity [FVC], andmaximum
voluntary ventilation [MVV])were converted to a 0–100 scalewith 0
being the worst possible result and 100 being the best possible result
(See Supplementaryfile 2 formoredetails). For eachpatient, efficacy
variables are only shown if measured at both baseline and week 48.
Safety results are presented for up to 96 weeks for the Modified
Intent-To-Treat (MITT) population consisting of all patients who
were randomized to study treatment and received at least one dose
of study drug.
RESULTS
Patient Characteristics
Of the 16patients enrolled inMOR-006, 15 receivedat least onedose
of study drug. The patient who did not receive any study treatment
couldnotphysically commit to the necessaryweekly travel.Of the 15
patients treated (MITT population), 12 completed at least 48 weeks
of study treatment.TwopatientsdiscontinuedERTat 4weeksdue to
grade 3 drug-related AEs (infusion related reaction and hypersensi-
tivity). One patient discontinued ERT at 21 weeks due to recurrent
urinary tract infections not related to the study drug. The MITT
population included six female and nine male patients; median age
at enrollment was 18.7 years (range 9.8–42.4). Of the 12 patients
completing 48weeks of study treatment, twomissedmore than 20%
of their scheduled infusions. Thus, theMPPpopulation consisted of
ten patients. Details of each of these 10 cases are included in
Supplementary file 3. MPP population demographics and baseline
characteristics are shown in Table I. All patients of the MPP
population had very short stature (90–110 cm) and severe skeletal
and joint abnormalities andmost had restrictive and/or obstructive
lung disease. All patients had a history of multiple surgeries,
including adenoidectomy/tonsillectomy, spinal cord decompres-
sion/fusion surgery, hip or knee surgery, or tracheotomy.Only three
patientswere able towalkon their feet at baseline, oneof themwith a
walking device. One patient (patient 8) had an inclusion/exclusion
TABLE I. Demographics and Baseline Characteristics of Patients Included in the Modified Per Protocol (MPP) Population
Patient
Age years at
baseline Sex
Age at Morquio A
diagnosis years
Lengtha
cm
Weight
kg
FDT
pegs/min
Method of
ambulation in T25FW
T25FW speed
feet/min
1 12.8 M 2.9 91 22.6 4.5 Crawling 6.9
2 18.9 M 2.3 NA 36.7 18.5 Knee walking 66.7
3 17.3 F 1.4 99 28.6 16.3 Crawling using arms
only
0.6
4 29.6 M 4.3 110 32.9 11.4 Physically unable NA
5 12.6 F 4.6 107 35.6 31.0 Physically unable NA
6 9.8 M 2.7 106 22.2 4.0 Physically unable NA
7 13.9 F 2.8 94 18.7 Physically
unable
Physically unable NA
8 42.2 M 42.4 90 21.2 31.0 Unassisted walking 88.2
9 31.0 M 3.9 103 37.5 13.5 Unassisted walking 21.4
10 24.5 F 3.0 97 22.3 24.0 Walker/walking frame 44.8
Mean
(SE)
21.3 (3.3) 99.6
(2.4)
27.8
(2.3)
17.1 (3.4) 38.1 (14.2)
FDT, functional dexterity test; T25FW, timed 25-foot walk; NA, not availabl.
aLength was measured as height was difficult to obtain for most patients.
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6MWT at baseline.Efficacy Results
Upper extremity function. The method used for the FDT was
customized for some patients based on their specific physical
disability (e.g., hypermobile, floppy wrists), as shown in a video
of patient 3 performing the test (Supplementary file 4). However,
the test was performed with similar methodology for any given
patient at all time points. In theMPP population, mean FDT speed
showed a trend toward improvement over 48 weeks, mainly in the
dominant hand (Fig. 1A). The mean (SE) number of pegs/min for
the dominant hand was 15.4 (3.5) at baseline (¼0.26 pegs/sec).
Mean (SE) change from baseline to week 48 was 1.4 (3.1) pegs/min.
However, the improvement in FDT speedwas largely caused by one
patient (patient 8) with an improvement of 22 pegs/min (Fig. 1B).
Of the nine patients who were able to perform the FDT at baseline,
four (patients 2, 5, 8, and 9) showed an improvement in FDT speed
over 48 weeks of1 peg/min, two patients (patients 4 and 6) were
stable, and two showed a decrease of 1 peg/min (patients 3 and
10) (Fig. 2). Patient 1 was unable to perform the test from week 36
onwards due to acute Morquio A disease-related complications
(spinal cord compression, see Supplementary file 3).
Upper extremity function was also assessed by grip and pinch
strength tests. Unfortunately,most patients had difficulty perform-
ing these test according to the study protocol, due toweak grip, very
hypermobile wrists and/or short stature (i.e., patients were unable
to put their feet on the floor) leading to differences in test execution
among centers. Regardless of test execution methods, grip and
pinch strength remained unchanged over the course of the study
(data not shown).
Basic mobility. Mean (SE) speed in the T25FW at baseline was
22.9 (10.3) feet/min for the MPP population. In several cases, theT25FW was not performed either at the discretion of the investi-
gator and/or for patients with significant pain. Six out of 10 patients
in the MPP population performed the T25FW at baseline and at
later visits, using different ambulation methods: three patients
walked (onewith the assistance of a walking device), one walked on
his knees (Supplementary file 5A), one crawled, and one used her
arms only (Supplementary file 5B). Patients were required to use a
consistent ambulation method throughout the study. Of the six
patients who performed the T25FW at baseline and later visits,
three (patients 2, 3, and 10) showed 10% improvement in speed
over 48 weeks (Fig. 3A), one (patient 8) showed a smaller improve-
ment (þ6.2%), one (patient 1) was unable to do the test from
week 36 onwards due to acute disease-related complications, and
one (patient 9) declined to do the test at 48 weeks as previous tests
caused too much pain afterwards.
Only four patients performed the T25FW at week 48; mean (SE)
change from baseline was 6.2 (3.6) feet/min. Although, the change
from baseline appeared small, it represents a mean (SE) improve-
ment of 75 (47) % for the four patients performing the test at both
baseline and week 48 (Fig. 3B). Due to the extremely limited
mobility at baseline, small improvements in T25FW speed repre-
sented great percent increases in some of the patients.
Only three patients from the MPP population (patients 2, 8,
and 9) were physically able to perform the 6MWT at baseline. Only
patient 8 performed the 6MWT at baseline and week 48, showing
an increase from 31.7m to 66.5m.
Respiratory function. Results showed poor respiratory func-
tion in all patients from the MPP population as compared to
patients from a Morquio A natural history study (MorCAP,
N¼ 325) [Harmatz et al., 2013]. At baseline, mean (SE) FVC
was 0.66 (0.06) L (N¼ 8) (vs. 1.1 L in patients 18 years and
1.5 L in patients >18 years from MorCAP), mean (SE) forced
expiratory volume in 1 sec (FEV1) was 0.49 (0.02) L (N¼ 8), and
mean (SE) MVV was 15.35 (1.3) L/min (N¼ 9) (vs. 32.4 L/min in
FIG. 1. Functional dexterity test (FDT) results. (A) Mean change
from baseline in FDT speed (dominant hand) over time in the
Modified Per Protocol (MPP) population (N¼ 10). Error bars
represent standard errors. (B) Individual patient FDT speed over
time.
FIG. 2. Summary table: outcome of efficacy assessments at
week 48 versus baseline (MPP population). Green, improved;
blue, stable; red, worsening; blank, test not performed or no data
available at baseline and/or week 48. Footnotes: aFDT improve-
ment, increase 1 pegs/min; stable, change <1 pegs/min;
worsening, decrease 1 pegs/min. bT25FW improvement,
increase speed of 10%; stable, change speed <10%; worsening,
decrease speed 10%. cAPPT pain intensity (Word Graphic Rating
Scale) improvement, decrease 1 point; stable, change <1
point; worsening, increase 1 point. dBPI-SF pain intensity
improvement, decrease 1 point; stable, change <1 point;
worsening, increase 1 point. ePODCI improvement, increase
10 points; stable, change <10 points; worsening, decrease
10 points. fSF-36 PCS improvement, increase 10 points;
stable, change <10 points; worsening, decrease 10 points.
gPIQ Breathing improvement, at least a little better; stable, no
change; worsening, at least a little worse. T25FW, patient did
not perform the test at 48 weeks because of pain after previous
tests.
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MorCAP) in the MPP population. Overall, FVC and FEV1
remained relatively stable andMVVincreased slightly over 48weeks
(Table II).Meanpercent change inMVVwasþ17.2%whereas FVC
decreased slightly (mean change 5.4%).
At an individual patient level, changes in FVC and FEV1 over
time varied considerably among patients; MVV improved over
48 weeks in all patients assessed, with five patients (patients 3, 4, 6,
9, and 10) showing an improvement of more than 10%. One
patient (patient 5) was physically unable to perform any of the
respiratory function tests throughout the study. Patient 9 was
physically unable to complete respiratory function tests, except
MVV, at baseline and week 24, but was able to perform all tests at
week 48.
Patient-reported outcomes. In theMPPpopulation, five of ten
patients reported virtually no pain (score2 on the pain intensity/
severity scale) at baseline in the APPT or BPI-SF. Two children
(patients 3 and 5) reported pain intensity scores of 5.3 and 5.5,
corresponding to medium pain [Jacob et al., 2014]. Three adult
patients (patients 4, 8, and 9) had pain intensity scores ranging
from three to seven and reported considerable pain interference
withwalking ability (pain interference scores 5–10). Unfortunately,
small sample sizes (due to the use of different tools in children
and adults) and high variability among patients precluded mean-
ingful collective analysis of data. Individual patient data showed areduction in pain intensity/severity (>1 point) over 48 weeks in
two of the five patients with pain at baseline (score>3 on the pain
intensity/severity scale; patients 3 and 8) (Fig. 2). Patient 3 also
stopped using non-steroidal topical analgesics during the study.
However, pain became more severe in two out of ten patients
(patients 7 and 9).
Quality of life scores at baseline were poor as compared to
healthy individuals. In children, baseline mean normalized self-
reported (N¼ 3) and parent-reported (N¼ 4) PODCI scores
were 41.33 (SE 11.5) and 39.25 (SE 8.2), respectively, versus
an average score of 50 in healthy individuals. In adults, baseline
mean SF-36 PCS was 17.3 (SE 4.5; N¼ 3), with 50 being the
average score in healthy individuals and 0 being the lowest score
possible. Mean SF-36 MCS was 57.7 (SE 5.0), similar to unaf-
fected individuals. Similar to the pain results, small sample sizes
due to different tools used in adults and children and great
FIG. 3. Timed 25-foot walk (T25FW) results. (A) Individual
patient T25FW speed over time. (B) Mean percent change from
baseline in T25FWT speed over time in the Modified Per Protocol
(MPP) population (N¼ 10). Error bars represent standard errors.
380 AMERICAN JOURNAL OF MEDICAL GENETICS PART Avariability among patients precluded meaningful evaluation of
mean changes in quality of life over 48 weeks. Individual patient
data showed stable quality of life scores in most patients (Fig. 2).
Patient 1 showed a considerable decrease (worsening) in the
parent-reported PODCI scale, most likely due to the acute
disease-related complications (spinal cord compression) he
experienced during the study.
On the PIQ, six of nine patients assessed (66.7%) reported
breathing ability had improved at least a little at week 48 compared
to baseline (patients 4 and 5 a little better, patient 7 much better,
andpatients 1, 2, and 8 verymuch better); three patients (patients 3,
6, and 9) reported no change in breathing ability. Patient 10 did not
perform the assessment at week 48.
Several patients showed improvements not captured by
the study assessments. Patient 3 reported increased ability toTABLE II. Respiratory Function Test Outcomes
Parameter Baseline mean (SE), N Week 48 mean (SE), N
FVC (L) 0.66 (0.06), N¼ 8 0.56 (0.05), N¼ 9
FEV1 (L) 0.49 (0.02), N¼ 8 0.48 (0.04), N¼ 9
MVV (L/min) 15.35 (1.3), N¼ 9 17.94 (1.5), N¼ 9
FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; MVV, maximum voluntary ventilaindependently perform activities such as computer typing, drink-
ing, reaching behind her head, and drinking from a cup. Patient 8
reported increased muscle strength and dramatic improvements
in sleep, breathing, and energy level. Patient 9 showed clear
improvements in energy level, speech, and breathing; this patient
was not able to lie flat on his back due to breathing problems at
baseline, but this improved during the study. Patient 10 showed
improved functional ability (she was able to comb her hair which
she had been previously unable to do for many years) and
improved speech (clearer voice and more understandable outside
close family members).
Urine KS. Treatment with elosulfase alfa led to a rapid and
sustained decrease in urine KS. At week 48, urine KSnormalized for
creatinine had decreased by amean (SE) of 52.4 (3.8)% in theMPP
population (Fig. 4).
Other efficacy outcomes. No conclusions can be made regard-
ing changes in anthropometric measurements, and radiographic
and DXA scans due to incomplete data collection and/or relatively
short follow-up time.
Overview of individual efficacy outcomes. Figure 2 gives an
overview of outcomes of efficacy measures at week 48 versus
baseline in the MPP population. All patients remained stable or
improved in multiple outcomes. Half of the patients did not show
worsening in any of the outcomes. Improvements in patient-
reported breathing ability (PIQ), FDT, and T25FW occurred
most frequently.Safety and Tolerability
The mean (SE) and range of total duration of elosulfase alfa
exposure in the MITT population (N¼ 15) were 62.1 (8.01) and
5–96 weeks, respectively. Mean number of drug infusions was 55.
Thirteen patients (86.7%)missed at least one infusion and a total of
119 (12.7%) planned infusions were missed.
Table III summarizes AEs in the MITT population. The most
frequently reported drug-related AEs were headache (40.0% of
patients), nausea, pyrexia, and vomiting (20.0% each). Six
patients (40%) had grade 3 AEs, but most drug-related AEs
were mild or moderate (CTCAE grade 1 or 2) in severity. Serious
adverse events (SAEs) occurred in 47% of patients; four study
drug-related SAEs were reported in two (13.3%) patients. Two
patients experienced AEs (grade 3 infusion-related reaction and
grade 3 hypersensitivity) that led to permanent discontinuation
of the study drug. Of a total of 819 infusions, 14 (1.7%) were
interrupted (11% or 1.3%) or discontinued (3% or 3.7%) due toin Modified Per Protocol (MPP) Population
Week 48 mean change (SE), N Week 48 mean % change (SE), N
0.07 (0.08), N¼ 8 5.4 (11.0), N¼ 8
0.01 (0.03), N¼ 8 1.4 (5.8), N¼ 8
2.59 (0.67), N¼ 9 17.2 (4.5), N¼ 9
tion; SE, standard error of the mean.
FIG. 4. Normalized urine keratan sulfate (KS) (mg/mg creati-
nine). Mean percent change from baseline in the Modified Per
Protocol (MPP) population (N¼ 10). Error bars represent
standard errors.
HARMATZ ET AL. 381an AE requiring medical intervention (IV steroids or
antihistamines).
All treated patients tested positive for anti-elosulfase alfa total
antibodies (TAb) by week 4 and remained positive for the
duration of the study. Neutralizing antibodies (NAb) developed
in all treated patients during the study and remained positive in
ten patients (66.7%) at week 48. No association was seen between
TAb titer or NAb positivity rate and percent change in urine KS
from baseline at weeks 24 and 48. There was also no relationship
between TAb titers and the occurrence of anaphylactic reactionsTABLE III. Safety Results
Elosulfase alfa
2.0mg/kg/week, N¼ 15
Any AE, N (%) 15 (100%)
Grade 1 1 (6.7%)
Grade 2 8 (53.3%)
Grade 3 6 (40.0%)
Any study drug-related AE, N (%) 13 (86.7%)
Grade 1 5 (33.3%)
Grade 2 6 (40.0%)
Grade 3 2 (13.3%)
Any study drug-related SAE, N (%) 2 (13.3%)
Grade 3 2 (13.3%)
Any AE leading to permanent study drug
discontinuation, N (%)
2 (13.3%)
Death, N (%) 0 (0.0%)
Number (%) infusions interrupted due to
an AE requiring medical intervention
11 (1.3%)
Number (%) infusions discontinued due to
an AE requiring medical intervention
3 (0.4%)
N, number of patients; EA, adverse event; SAE, serious adverse event.or study drug discontinuation. All subjects tested negative for
drug-specific IgE.DISCUSSION
ERTwith elosulfase alfa is currently the only approved therapy that
directly targets the underlying cause of Morquio A syndrome.
Before its introduction, management of Morquio A patients was
limited to symptommanagement and palliative care. Clinical trials
have demonstrated that elosulfase alfa has a positive efficacy-safety
profile [Hendriksz et al., 2014a; Burton et al., 2015].However, these
trials included only patients able towalk at least 30m in the 6MWT.
MOR-006 is the first study to assess the efficacy and safety of
elosulfase alfa ERT in patients with limited ambulation, represent-
ing the group with severe and fixed burden of disease.
As could be expected, the patients in this study were on average
older and more severely affected than the patients in other elo-
sulfase alfa studies (Supplementary file 3) [Hendriksz et al., 2014a;
Burton et al., 2015]. Only six of the ten patients included in the
efficacy analysis (MPP population) were able to ambulate, either by
walking (three patients, including one with the assistance of
a walker) or by using other ambulation methods such as knee
walking or crawling (Supplementary files 3 and 5). All patients
showed poor dexterity in the FDT compared with a healthy
population (Supplementary file 4); one patient from the MPP
population was unable to perform the FDT. The mean baseline
dexterity speed of 0.26 pegs/sec was below that reported for 3-year-
old healthy children (0.41 pegs/sec) [Gogola et al., 2013]. Patients
also showed more compromised respiratory function as compared
to patients included in MorCAP, which likely relates to their
shorter stature [Harmatz et al., 2013]. Although, all patients had
severe disabilities, half of them reported no pain at baseline, most
likely due to inactive lifestyle. Previous research showed that pain is
an important feature of Morquio A, but that wheelchair-bound
Morquio A patients experience less pain thanmoremobile patients
[Hendriksz et al., 2014b]. The same study also showed that less
mobile patients have worse quality of life. The very poor quality of
life scores in the MOR-006 population seem to confirm these
findings. The mean SF-36 PCS in adult patients from MOR-006
(17.3) was much lower than that recently reported for 20 adult
Morquio A patients (36.5) [Ali and Cagle, 2015].
Evaluating the efficacy of ERT in this very disabled patient
population proved to be challenging. Several of the severe manifes-
tations, particularly skeletal abnormalities, were not expected to
improvewithERT.Another important issuewas that the6MWT, the
primary efficacy measure in the pivotal phase 3 study, was not a
feasible assessment in MOR-006 as most patients were unable to
walk. Therefore, endpoints used in the study were exploratory in
nature, which led to difficulties evaluating the efficacy of treatment.
Upper extremity function, basic mobility in the T25FW, pain, and
quality of life questionnaireswereused as primary efficacymeasures.
Upper extremity function tests were difficult to perform according
to the testing protocol because of the patients’ short stature and/or
weak grip due to wrist deformity and hypermobility. Results of the
upper extremity function tests (FDT and pinch/grip tests) and the
T25FWwerenot comparable among individualsdue tovariability in
test execution because of severe disease limitations. In addition,
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centers, patients who were unable to walk were allowed to use
different ambulation methods, such as crawling or knee walking,
while other sites did not perform the test in patients unable to walk
on their feet. It should be noted that the original T25FW, developed
for use in patients with multiple sclerosis, does not allow any
ambulation methods other than walking [Polman and Rudick,
2010].The interpretationof thepainandqualityof life questionnaire
results was hampered by great variability in outcomes between and
withinpatients and small sample sizes, asdifferent testswereused for
children and adults. Psychological, social, and logistical issues also
influenced treatmentoutcomes in somecases. For somepatients, the
burden of traveling long distances for infusions and assessments
might have limited the beneficial effects of ERT. One of the patients
wasverydemotivatedby fearof losing fundingandcare support ifhis
condition should improve.
Because of the great clinical heterogeneity between the patients
included in this study, treatmentgoalsdiffered frompatient topatient.
In addition, problems with test execution depended on the unique
physical limitations of each patient. Therefore, there was not a single
measure that was able to capture meaningful changes in all patients,
underlining the need to evaluate the impact of treatment on an
individual basis in severely disabled Morquio A patients. Deciding
which tests should be used in a specific patient to evaluate treatment
impact is challenging and should be based on several criteria, includ-
ing the type and severity (in terms of the impact on the patient’s daily
living) of clinical manifestations, the potential for improvement in
these clinical manifestations, the capability of the patient to perform
the test, and the patient’s expectations of treatment.
Despite the severephysical limitationsof thepatients andproblems
with test execution and interpretation, improvements from baseline
were seen in several outcomemeasures after 48 weeks of ERT inmost
patients. Mean dexterity speed increased in half of the patients tested
and remained stable in 25%. Notably, most of these patients were
adults, whereas in a healthy population average dexterity speed
declinesafter theageof17years [AaronandJansen,2003]. Inaddition,
most patients who were able to perform the T25FW at baseline
showed increased speed over time. Factors that may have improved
performance in this test (e.g., pain, fatigue, muscle strength, respira-
tory function)differ frompatient topatient.However,aspatientsused
their usual method of ambulation (walking, crawling, knee walking),
any improvement is expected to facilitate their ability to perform
activities of daily living. In addition, patient-reported impression of
breathing ability (PIQ) improved inmost cases. Although, all patients
showed small improvements inMVV, nomeaningful improvements
in FVC and FEV1 were seen over 48 weeks. The difference between
MVVand spirometry resultsmay be due to the fact that theMVV test
is easier to perform than spirometery in a severely limited population
and may be influenced more by changes in neuromuscular function.
Longer follow-up timemay be necessary to identify positive effects of
treatment on respiratory function. Long-term (120-week) follow-up
data from the extension of the elosulfase alfa phase 3 study (MOR-
005) showed early improvements inMVV followedby improvements
in FEV1 and FVC which developed over the course of the extension
study [Hendriksz et al., 2014a, 2016a]. Importantly, several patients
reported subjective improvements thatwerenotcapturedby the study
assessments, suchas increased energyandbetter ability to type, lift anddrink from a cup, comb hair, or stand up without braces. Some of
these improvementswerereported togreatly impact thepatient’sdaily
life, but these improvements are not capturedby current quality of life
tools. Of the ten patients in the MPP population, only one discon-
tinuedERTafter the study.Ninepatients continuedontherapy,which
means that they have gained enough benefit to endure a once weekly
infusion lasting about 7 hr from set-up to end.
The dose of elosulfase alfa of 2.0mg/kg/week used in this study is
the recommended dose as established in a previous dose-escalation
study and the pivotal phase 3 study (MOR-004) [Hendriksz et al.,
2012, 2014a]. As the pivotal study excluded Morquio A patients
with limited ambulation, it is uncertain whether this is also the
optimal dosing regimen for patients with more advanced disease;
future study is warranted.
The safety analysis of MOR-006 showed that the nature of AEs
was generally consistent with other studies in Morquio A patients
[Hendriksz et al., 2014a; Burton et al., 2015]. However, severity and
impact of AEs were somewhat greater, as was to be expected with
this sicker patient population (a larger percent of grade 3 AEs and
SAEs overall and more AE-associated discontinuations). Overall,
1.7% of infusions were interrupted or discontinued due to an AE in
MOR-006 versus 1.3% in the phase 3 MOR-004 study [Hendriksz
et al., 2014a]. Antibody development was universal, similar to
previous studies [Hendriksz et al., 2014a; Burton et al., 2015]. This
initial antibody development had no apparent impact on the
efficacy or safety of ERT. The impact of persistent and increasing
antibody titers needs to be studied in the long-term.CONCLUSIONS
TheMOR-006 study demonstrates that ERT with elosulfase alfa has
an acceptable safety profile, even in severely disabled Morquio A
patients who may not tolerate even mild infusion related reactions,
and suggests thepotential for beneficial effects in thesepatients.Most
patients experienced improvement in at least one of the domains
assessed. However, lack of validated tools, issues with test execution,
small sample sizes, irreversibility of some symptoms, and clinical
heterogeneity among patients hampered interpretability of out-
comes across the study. In addition, important patient-reported
improvements in ability to carry out activities of daily livingwere not
captured well by study assessments. As traditional tools were devel-
oped for mean populations and not for the extremes, the challenge
will be to develop tools andmeasures that could capture the patient-
reported benefits in this severely affected patient population. The
outcomes of this study also stress the need to examine the impact of
elosulfase alfa on an individual basis in severely disabledMorquio A
patients. Regardless of which assessments are determined to be the
most feasible and appropriate for a particular patient, collection of
pre-treatment data and consistent assessment execution methodol-
ogy are essential for capturing the effects of ERT.ACKNOWLEDGMENTS
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